140 related articles for article (PubMed ID: 3675872)
1. Hydrolysis of human high-molecular-mass kininogen by human plasma kallikrein. Proposal of a new model concept for the course of reaction in presence and absence of C1(-)-inhibitor.
Wiedler J; Dutler H
Biol Chem Hoppe Seyler; 1987 Sep; 368(9):1203-13. PubMed ID: 3675872
[TBL] [Abstract][Full Text] [Related]
2. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor.
Silverberg M; Longo J; Kaplan AP
J Biol Chem; 1986 Nov; 261(32):14965-8. PubMed ID: 3639874
[TBL] [Abstract][Full Text] [Related]
3. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen.
Schapira M; Scott CF; Colman RW
Biochemistry; 1981 May; 20(10):2738-43. PubMed ID: 6910423
[TBL] [Abstract][Full Text] [Related]
4. Studies on human kininogens. I. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW)-kininogen.
Nakayasu T; Nagasawa S
J Biochem; 1979 Jan; 85(1):249-58. PubMed ID: 104988
[TBL] [Abstract][Full Text] [Related]
5. Interaction of human plasma kallikrein and its light chain with C1 inhibitor.
van der Graaf F; Koedam JA; Griffin JH; Bouma BN
Biochemistry; 1983 Sep; 22(20):4860-6. PubMed ID: 6556071
[TBL] [Abstract][Full Text] [Related]
6. Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen.
Kleniewski J; Donaldson VH
J Lab Clin Med; 1987 Apr; 109(4):469-79. PubMed ID: 2950194
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of kallikrein in human plasma.
van der Graaf F; Koedam JA; Bouma BN
J Clin Invest; 1983 Jan; 71(1):149-58. PubMed ID: 6184384
[TBL] [Abstract][Full Text] [Related]
8. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein.
Mori K; Nagasawa S
J Biochem; 1981 May; 89(5):1465-73. PubMed ID: 6168636
[TBL] [Abstract][Full Text] [Related]
9. Hydrolysis of rat high molecular weight kininogen by purified rat urinary kallikrein: identification of bradykinin as the kinin formed.
Girolami JP; Alhenc-Gelas F; Dos Reis ML; Bascands JL; Suc JM; Corvol P; Menard J
Adv Exp Med Biol; 1986; 198 Pt A():137-45. PubMed ID: 3643701
[TBL] [Abstract][Full Text] [Related]
10. Kininogen-derived fluorogenic substrates for investigating the vasoactive properties of rat tissue kallikreins--identification of a T-kinin-releasing rat kallikrein.
El Moujahed A; Brillard-Bourdet M; Juliano MA; Moreau T; Chagas JR; Gutman N; Prado ES; Gauthier F
Eur J Biochem; 1997 Jul; 247(2):652-8. PubMed ID: 9266709
[TBL] [Abstract][Full Text] [Related]
11. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
Olson ST; Sheffer R; Francis AM
Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
[TBL] [Abstract][Full Text] [Related]
12. Further characterization of monoclonal antibodies against rat plasma kallikrein, rat low molecular weight kininogen and synthetic bradykinin.
Bedi GS; Back N
Adv Exp Med Biol; 1989; 247B():223-30. PubMed ID: 2610064
[TBL] [Abstract][Full Text] [Related]
13. Canine plasma kininogen: evidence for the presence of two kininogens and purification of high molecular weight kininogen and characterization as multi-functional molecule.
Mashiko H; Takahashi H
Comp Biochem Physiol B Biochem Mol Biol; 1997 Aug; 117(4):535-43. PubMed ID: 9297798
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of kinin release from human low-molecular-mass-kininogen by the synergistic action of human plasma kallikrein and leukocyte elastase.
Sato F; Nagasawa S
Biol Chem Hoppe Seyler; 1988 Sep; 369(9):1009-17. PubMed ID: 3228488
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin.
Kleniewski J; Blankenship DT; Cardin AD; Donaldson V
J Lab Clin Med; 1992 Jul; 120(1):129-39. PubMed ID: 1535355
[TBL] [Abstract][Full Text] [Related]
16. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
Kaplan AP
Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
18. Studies on human high molecular weight (HMW) kininogen. III. Cleavage of HMW kininogen by the action of human salivary kallikrein.
Mori K; Sakamoto W; Nagasawa S
J Biochem; 1981 Aug; 90(2):503-9. PubMed ID: 6913579
[TBL] [Abstract][Full Text] [Related]
19. High molecular weight kininogen: its inability to correct the clotting of kininogen-deficient plasma after cleavage of bradykinin by plasma kallikrein, plasmin or trypsin.
Chan JY; Movat HZ; Burrowes CE
Thromb Res; 1979; 14(6):817-24. PubMed ID: 157559
[No Abstract] [Full Text] [Related]
20. Surface-induced alterations in the kinetic pathway for cleavage of human high molecular weight kininogen by plasma kallikrein.
Tayeh MA; Olson ST; Shore JD
J Biol Chem; 1994 Jun; 269(23):16318-25. PubMed ID: 8206938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
